Provided by Tiger Fintech (Singapore) Pte. Ltd.

AzurRx Biopharma Inc.

3.45
+0.0000
Volume:- -
Turnover:2.20M
Market Cap:34.33M
PE:-0.22
High:3.45
Open:3.45
Low:3.45
Close:3.45
Loading ...

BRIEF-AzurRx Biopharma Inc Says Received Letter From Nasdaq Indicating Co Is Currently Not In Compliance With Listing Requirement

Reuters
·
18 Jun 2021

BRIEF-AzurRx Biopharma Doses First Patient In Phase 2 Clinical Trial Of Niclosamide For The Treatment Of Covid-19 Gastrointestinal Infections

Reuters
·
07 Jun 2021

BRIEF-Azurrx Biopharma Says Entered Into Market Offering Agreement Relating To Sale Of Common Shares Of Up To $50 Mln From Time To Time

Reuters
·
04 Jun 2021

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

GlobeNewswire
·
19 May 2021

AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency

Benzinga
·
13 May 2021

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

GlobeNewswire
·
12 May 2021

AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

GlobeNewswire
·
11 May 2021

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire
·
15 Apr 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial

StreetInsider
·
14 Apr 2021

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

GlobeNewswire
·
13 Apr 2021

AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections

Benzinga
·
06 Apr 2021

BRIEF-AzurRx Biopharma Initiates Phase 2 Clinical Trial Of Niclosamide For Treatment Of Covid-19 Gastrointestinal Infections

Reuters
·
06 Apr 2021

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire
·
06 Apr 2021

AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study

Benzinga
·
01 Apr 2021

BRIEF-AzurRx Biopharma Provides Key Takeaways From Phase 2B Option 2 Clinical Trial Topline Results Conference Call

Reuters
·
01 Apr 2021

After-Hours Stock Movers 03/31: (QS) (IDEX) (GES) Higher; (AZRX) (XL) (MARK) Lower (more...)

StreetInsider
·
01 Apr 2021